CURRENT
ISSUE
1750
March 16, 2026
Description
Two oral bacterial type II topoisomerase inhibitors.
Indication
Treatment of uncomplicated urogenital gonorrhea in patients ≥12 years old who weigh ≥45 kg (gepotidacin) or ≥35 kg (zoliflodacin); gepotidacin is only approved for use in patients with limited or no alternative treatment options.
Efficacy
In randomized trials in patients with uncomplicated urogenital gonorrhea, microbiological cure rates with 2 doses of gepotidacin or a single dose of zoliflodacin were noninferior to those with ceftriaxone plus azithromycin.
Adverse Effects... Continue reading
More from Issue 1750
Previous Issue: 1749
March 2, 2026
- Drugs for Atopic Dermatitis
- In Brief: Extended Duration of Use for Nexplanon
- Addendum: Urinary Incontinence with Second-Generation Antipsychotic Drugs
- Comparison Chart: Topical Nonsteroidal Drugs for Atopic Dermatitis (online only)
- Comparison Chart: Interleukin (IL) Antagonists and Oral JAK Inhibitors for Moderate to Severe Atopic Dermatitis (online only)
Coming Soon
Drugs for Cognitive Loss and Dementia
Aflibercept (Eylea HD) for Macular Edema following Retinal Vein Occlusion
Pivmecillinam (Pivya) for Uncomplicated UTI
Donate
Subscribe
Follow us
FROM
ISSUE
ISSUE
1750
Description: A long-acting interleukin-5 (IL-5) antagonist
Indication: Add-on maintenance treatment of severe asthma characterized by an eosinophilic phenotype in patients ≥12 years old
Efficacy: Addition of depemokimab to background asthma therapy reduced the rate of asthma exacerbations in two randomized controlled trials in patients with poorly controlled asthma and elevated eosinophil levels.
Adverse Effects: Most common were upper respiratory tract infection, allergic rhinitis, influenza, arthralgia, and pharyngitis. Serious hypersensitivity reactions can occur.
Dosage: 100 mg SC every 6 months, administered by a healthcare professional
Cost: One year of treatment costs about $52,000.
Conclusion: Depemokimab can reduce the rate of asthma exacerbations in patients with severe eosinophilic asthma. It is administered less frequently than other drugs approved for … Continue reading